Vanguard Group’s Enliven Therapeutics ELVN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $48.4M | Buy |
2,410,636
+438,397
| +22% | +$8.79M | ﹤0.01% | 2137 |
|
|
2025
Q1 | $38.8M | Sell |
1,972,239
-3,416
| -0.2% | -$67.2K | ﹤0.01% | 2201 |
|
|
2024
Q4 | $44.5M | Buy |
1,975,655
+55,283
| +3% | +$1.24M | ﹤0.01% | 2212 |
|
|
2024
Q3 | $49M | Buy |
1,920,372
+98,912
| +5% | +$2.53M | ﹤0.01% | 2186 |
|
|
2024
Q2 | $42.6M | Buy |
1,821,460
+638,194
| +54% | +$14.9M | ﹤0.01% | 2210 |
|
|
2024
Q1 | $20.8M | Sell |
1,183,266
-47,622
| -4% | -$838K | ﹤0.01% | 2578 |
|
|
2023
Q4 | $17M | Buy |
1,230,888
+79,071
| +7% | +$1.09M | ﹤0.01% | 2666 |
|
|
2023
Q3 | $15.7M | Buy |
1,151,817
+9,313
| +0.8% | +$127K | ﹤0.01% | 2648 |
|
|
2023
Q2 | $23.3M | Buy |
1,142,504
+990,590
| +652% | +$20.2M | ﹤0.01% | 2529 |
|
|
2023
Q1 | $3.33M | Sell |
151,914
-289,299
| -66% | -$6.34M | ﹤0.01% | 3492 |
|
|
2022
Q4 | $1.8M | Buy |
441,213
+137,058
| +45% | +$561K | ﹤0.01% | 3702 |
|
|
2022
Q3 | $693K | Buy |
304,155
+38,468
| +14% | +$87.6K | ﹤0.01% | 4113 |
|
|
2022
Q2 | $324K | Hold |
265,687
| – | – | ﹤0.01% | 4389 |
|
|
2022
Q1 | $500K | Sell |
265,687
-218,217
| -45% | -$411K | ﹤0.01% | 4399 |
|
|
2021
Q4 | $1.09M | Sell |
483,904
-1,000
| -0.2% | -$2.25K | ﹤0.01% | 4245 |
|
|
2021
Q3 | $1.98M | Buy |
484,904
+293,493
| +153% | +$1.2M | ﹤0.01% | 4057 |
|
|
2021
Q2 | $1.51M | Sell |
191,411
-38,698
| -17% | -$306K | ﹤0.01% | 4047 |
|
|
2021
Q1 | $1.94M | Buy |
230,109
+20,068
| +10% | +$169K | ﹤0.01% | 3868 |
|
|
2020
Q4 | $4.63M | Buy |
210,041
+17,717
| +9% | +$391K | ﹤0.01% | 3397 |
|
|
2020
Q3 | $3.91M | Sell |
192,324
-4,371
| -2% | -$88.9K | ﹤0.01% | 3276 |
|
|
2020
Q2 | $5.44M | Buy |
196,695
+159,371
| +427% | +$4.4M | ﹤0.01% | 3061 |
|
|
2020
Q1 | $599K | Buy |
+37,324
| New | +$599K | ﹤0.01% | 3635 |
|